Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05652868




Registration number
NCT05652868
Ethics application status
Date submitted
29/11/2022
Date registered
15/12/2022
Date last updated
13/06/2024

Titles & IDs
Public title
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
Scientific title
A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01
Secondary ID [1] 0 0
KisMET-01
Secondary ID [2] 0 0
MYTX-011-01
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
NSCLC 0 0
NSCLC Stage IV 0 0
NSCLC Stage IIIB 0 0
Non-Small Cell Lung Cancer 0 0
Advanced Non-Small Cell Squamous Lung Cancer 0 0
Advanced Non-Small Cell Lung Cancer 0 0
Advanced Non-Small Cell Non-Squamous Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - MYTX-011

Experimental: Part 1 Dose Escalation - Part 1 patients will receive MYTX-011.

Experimental: Part 2 Cohort A - Part 2 Cohort A patients will be randomized to two different dose levels of MYTX-011. Doses to be determined after completion of Part 1.

Experimental: Part 2 Cohort B - Part 2 Cohort B patients will receive MYTX-011 at the recommended phase 2 dose.

Experimental: Part 2 Cohort C - Part 2 Cohort C patients will receive MYTX-011 at the recommended phase 2 dose.

Experimental: Part 2 Cohort D - Part 2 Cohort D patients will receive MYTX-011 at the recommended phase 2 dose.

Experimental: Part 2 Cohort E - Part 2 Cohort E patients will receive MYTX-011 at the recommended phase 2 dose.


Treatment: Drugs: MYTX-011
MYTX-011 will be administered as an intravenous infusion every 21 days.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Part 1: Number of patients with dose limiting toxicity (DLT)
Timepoint [1] 0 0
Up to Day 21
Primary outcome [2] 0 0
Part 2: Number of patients with tumor response
Timepoint [2] 0 0
2 years
Secondary outcome [1] 0 0
Part 1: Pharmacokinetic (PK) parameter (Total ADC)
Timepoint [1] 0 0
24 months
Secondary outcome [2] 0 0
Part 1: Pharmacokinetic (PK) parameter (Total antibody)
Timepoint [2] 0 0
24 months
Secondary outcome [3] 0 0
Part 1: Pharmacokinetic (PK) parameter (Free MMAE)
Timepoint [3] 0 0
24 months
Secondary outcome [4] 0 0
Part 1: ADA
Timepoint [4] 0 0
24 months
Secondary outcome [5] 0 0
Part 1: ORR
Timepoint [5] 0 0
24 months
Secondary outcome [6] 0 0
Part 1: DOR, TTR, DCR
Timepoint [6] 0 0
2 years
Secondary outcome [7] 0 0
Part 1: PFS
Timepoint [7] 0 0
for up to 2 years after end of treatment
Secondary outcome [8] 0 0
Part 1: OS
Timepoint [8] 0 0
for up to 2 years after end of treatment

Eligibility
Key inclusion criteria
Part 1:

* Histologically or cytologically confirmed locally advanced, recurrent or metastatic NSCLC and have received available standard of care therapy.
* There is no limit on the number of prior therapies that can have been received.

Part 2:

Cohort A:

* Have histologically or cytologically confirmed locally advanced, recurrent (and not a candidate for curative therapy), or metastatic non-squamous NSCLC.
* Tumor sample with high cMET expression by IHC confirmed by central laboratory testing.

Cohort B:

* Have histologically or cytologically confirmed locally advanced, recurrent (and not a candidate for curative therapy), or metastatic non-squamous NSCLC.
* Tumor sample with intermediate cMET expression by IHC confirmed by central laboratory testing.

Cohort C:

* Have histologically or cytologically confirmed locally advanced, recurrent (and not a candidate for curative therapy), or metastatic squamous NSCLC.
* Tumor sample with cMET overexpression by IHC confirmed by central laboratory testing.

Cohort D:

* Have histologically or cytologically confirmed locally advanced, recurrent (and not a candidate for curative therapy), or metastatic NSCLC.
* Tumor sample that does not meet cMET IHC entry criteria for Cohorts A-C
* Known MET amplification or exon 14 skipping mutations respectively. Patients with MET exon 14 skipping mutations must have received MET TKI therapy if available and considered standard of care.

Cohort E:

* Have histologically or cytologically confirmed locally advanced, recurrent (and not a candidate for curative therapy), or metastatic NSCLC.
* Evidence of cMET expression by IHC as documented in medical records.
* No more than 3 prior lines of systemic therapy including prior cMET targeted ADC or antibody.

Part 2 Cohorts A-D

- No more than two prior lines of therapy in the locally advanced/metastatic setting.

Part 2 Cohorts A-E:

* Known to not have an actionable EGFR mutation. Patients with or without other driver mutations are permitted to enroll.
* Patients without any actionable gene alteration: must have progressed on (or be considered ineligible for) standard of care therapy
* Patients with actionable gene alterations (other than EGFR) must have progressed on (or be considered ineligible for) or be intolerant to anti-cancer therapy targeting driver gene alterations and available standard of care therapy

All patients (Part 1 and Part 2)

* Patient has at least one measurable lesion per RECIST 1.1
* ECOG performance status 0 or 1
* For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective method of birth control for the duration of the study treatment and for at least 6 months after the last dose of study drug.
* Able to provide informed consent, and willing and able to comply with study protocol requirements
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Radiation to the lung within 2 months prior to screening.
* Major surgery within 28 days of first dose of study drug administration.
* Untreated, uncontrolled CNS metastases.
* History of interstitial lung disease or pneumonitis that required treatment with systemic steroids or evidence of active interstitial lung disease or pneumonitis. A history of prior radiation pneumonitis in the radiation field (fibrosis) is permitted.
* Clinically significant systemic illness that could pose undue risk to the subject or confound the ability to interpret study results.
* Active infection requiring IV antibiotics, antivirals, or antifungal medication
* Neuropathy > Grade 1
* History of cirrhosis, hepatic fibrosis, esophageal or gastric varices, or other clinically significant liver disease.
* Active or chronic corneal disorder

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
23/03/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2027
Actual
Sample size
Target
150
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA
Recruitment hospital [1] 0 0
KisMET-01 Clinical Site - Blacktown
Recruitment hospital [2] 0 0
KisMET-01 Clinical Site - Camperdown
Recruitment hospital [3] 0 0
KisMET-01 Clinical Site - Adelaide
Recruitment postcode(s) [1] 0 0
2148 - Blacktown
Recruitment postcode(s) [2] 0 0
2050 - Camperdown
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
5011 - Adelaide
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Georgia
Country [3] 0 0
United States of America
State/province [3] 0 0
Illinois
Country [4] 0 0
United States of America
State/province [4] 0 0
Massachusetts
Country [5] 0 0
United States of America
State/province [5] 0 0
Nebraska
Country [6] 0 0
United States of America
State/province [6] 0 0
New Jersey
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
Pennsylvania
Country [9] 0 0
United States of America
State/province [9] 0 0
South Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Tennessee
Country [11] 0 0
United States of America
State/province [11] 0 0
Texas
Country [12] 0 0
United States of America
State/province [12] 0 0
Virginia
Country [13] 0 0
United States of America
State/province [13] 0 0
Wisconsin
Country [14] 0 0
Korea, Republic of
State/province [14] 0 0
Goyang
Country [15] 0 0
Korea, Republic of
State/province [15] 0 0
Incheon
Country [16] 0 0
Korea, Republic of
State/province [16] 0 0
Seoul
Country [17] 0 0
Spain
State/province [17] 0 0
Madrid
Country [18] 0 0
United Kingdom
State/province [18] 0 0
London
Country [19] 0 0
United Kingdom
State/province [19] 0 0
Oxford

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Mythic Therapeutics
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase I open label multi-center study to evaluate the safety, tolerability, pharmacokinetics and preliminary effectiveness of the investigational drug MYTX-011 in patients with locally advanced, recurrent or metastatic NSCLC. MYTX-011 is in a class of medications called antibody drug conjugates (ADCs). MYTX-011 is composed of a pH-dependent anti-cMET antibody and the potent antimicrotubule drug monomethyl auristatin E (MMAE).
Trial website
https://clinicaltrials.gov/study/NCT05652868
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Ting Wu, MD MSc
Address 0 0
Mythic Therapeutics
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
William T Downing
Address 0 0
Country 0 0
Phone 0 0
1-833-888-1138
Fax 0 0
Email 0 0
clinicalsupport@mythictx.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05652868